Director Birger Johannes Meyer-Gloeckner filed a Form 4 with the SEC on September 8, 2026, disclosing a net stock option exercise and same-day sale of ordinary shares in ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) on September 4, 2026.
Theodore Alan Huizenga, SVP and Chief Accounting Officer of Ultragenyx Pharmaceutical Inc., filed a Form 4 on September 8, 2026, disclosing a sale of common stock on September 3, 2026, related to RSU vesting.
Ronald Kyle Kettler, Chief Financial Officer of Granite Ridge Resources, Inc., filed a Form 4 on September 8, 2026, reporting a purchase of 6,000 shares of common stock on September 4, 2026.
Bruno Sousa Mauad, a director of Aura Minerals Inc. (NASDAQ:AUGO), filed a statement of changes in beneficial ownership on September 8, 2026, reporting the settlement of a cash-settled total return swap transacted on September 4, 2026.
Jeffery V. Curry, Chief Legal Officer and Secretary of CBL & Associates Properties Inc, filed a Form 4 on September 8, 2026, disclosing a sale of common stock that occurred on September 3, 2026.
Japan Post Holdings Co., Ltd. filed a Form 4 with the SEC on September 8, 2026, disclosing a sale of Aflac Inc. common stock executed on September 3, 2026, pursuant to a Rule 10b5-1 plan.
Yael Brenner, VP Quality at Kamada Ltd, filed a Form 4 on September 8, 2026, disclosing a net exercise of employee stock options in ordinary shares on September 2, 2026.
Aktis Oncology (NASDAQ:AKTS) shares are sliding sharply as the stock gives back recent gains, trading down after touching a high near $26.99 earlier in the session onVolumeroughly in line with average. Aktis Oncology is a clinical-stage biotechnology company focused on developing targetedAlpharadiopharmaceutical therapies to …
A NASDAQ-listed biotechnology company is trading sharply lower today, on pace for one of its worst single-day losses since 2001, despite announcing landmark survival data for one of its cancer therapies, an outcome that would typically be read as good news for the stock. …
A Form 4 filed on September 8, 2026 by David Tsur, a director of Kamada Ltd (NASDAQ:KMDA), discloses the net exercise of two employee stock option grants covering a combined 49,000 ordinary shares on September 2, 2026.